CA3073925A1 - Treatment of cns conditions - Google Patents

Treatment of cns conditions Download PDF

Info

Publication number
CA3073925A1
CA3073925A1 CA3073925A CA3073925A CA3073925A1 CA 3073925 A1 CA3073925 A1 CA 3073925A1 CA 3073925 A CA3073925 A CA 3073925A CA 3073925 A CA3073925 A CA 3073925A CA 3073925 A1 CA3073925 A1 CA 3073925A1
Authority
CA
Canada
Prior art keywords
bipyridin
hydroxypiperidin
methanone
pharmaceutically acceptable
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3073925A
Other languages
English (en)
French (fr)
Inventor
Toshiya Nishi
Shinichi Kondo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA3073925A1 publication Critical patent/CA3073925A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CA3073925A 2017-08-31 2018-08-30 Treatment of cns conditions Pending CA3073925A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553070P 2017-08-31 2017-08-31
US62/553,070 2017-08-31
PCT/JP2018/032949 WO2019045121A1 (en) 2017-08-31 2018-08-30 TREATMENT OF CNS DISEASES

Publications (1)

Publication Number Publication Date
CA3073925A1 true CA3073925A1 (en) 2019-03-07

Family

ID=63722720

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073925A Pending CA3073925A1 (en) 2017-08-31 2018-08-30 Treatment of cns conditions

Country Status (8)

Country Link
US (4) US11285139B2 (https=)
EP (1) EP3675852A1 (https=)
JP (2) JP7196157B2 (https=)
KR (1) KR102680786B1 (https=)
CN (2) CN116370475A (https=)
CA (1) CA3073925A1 (https=)
MX (1) MX2020001732A (https=)
WO (1) WO2019045121A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119192266A (zh) 2011-10-14 2024-12-27 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2848823T3 (es) 2013-08-23 2021-08-12 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016123056A1 (en) 2015-01-26 2016-08-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
PT3711758T (pt) 2017-11-14 2024-04-22 Sk Biopharmaceuticals Co Ltd Utilização de composto de carbamato para prevenir, aliviar ou tratar crise de ausência ou epilepsia que apresenta crise de ausência
WO2020021372A1 (en) * 2018-07-24 2020-01-30 Zenvision Pharma Llp Nasal drug delivery system of brivaracetam or salt thereof thereof
GB2580881A (en) * 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
JP2023504177A (ja) * 2019-12-02 2023-02-01 エフ．ホフマン－ラ ロシュ アーゲー アルキニル－（ヘテロアリール）－カルボキサミドｈｃｎ１阻害剤
GB2597285A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597312A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
US20240197704A1 (en) * 2021-04-09 2024-06-20 Johns Hopkins University Treatment methods and compositions comprising perampanel
CN115487144A (zh) * 2021-06-18 2022-12-20 北京万全德众医药生物技术有限公司 一种卢非酰胺的口服液制备方法
WO2023175591A1 (en) * 2022-03-18 2023-09-21 Takeda Pharmaceutical Company Limited Methods of treating neurological diseases
WO2024100531A1 (en) * 2022-11-07 2024-05-16 Takeda Pharmaceutical Company Limited Method of treating seizure disorders
WO2025126159A1 (en) * 2023-12-15 2025-06-19 Takeda Pharmaceutical Company Limited A method for treating a neurological disease in a recreational drug user
WO2025257799A1 (en) * 2024-06-14 2025-12-18 Takeda Pharmaceutical Company Limited Methods of treating dravet syndrome
CN121550436A (zh) * 2026-01-23 2026-02-24 四川大学华西医院 新靶点在结节性硬化症相关癫痫中的应用、组合物及联合用药方式

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2763979T3 (pl) 2011-10-07 2019-06-28 Takeda Pharmaceutical Company Limited Związki 1-arylokarbonyl-4-oksy-piperydynowe użyteczne do leczenia chorób neurodegeneracyjnych
PE20151162A1 (es) 2012-12-11 2015-08-28 Takeda Pharmaceutical Compuestos heterociclicos inhibidores del colesterol 24-hidroxilasa (ch24h)
JP6272832B2 (ja) 2013-04-04 2018-01-31 武田薬品工業株式会社 複素環化合物
JP6807322B2 (ja) 2015-10-16 2021-01-06 武田薬品工業株式会社 複素環化合物の製造方法

Also Published As

Publication number Publication date
JP2020532508A (ja) 2020-11-12
CN111065394B (zh) 2023-03-31
EP3675852A1 (en) 2020-07-08
JP7469445B2 (ja) 2024-04-16
JP2023027267A (ja) 2023-03-01
CN116370475A (zh) 2023-07-04
US20220168294A1 (en) 2022-06-02
US20250281477A1 (en) 2025-09-11
US20230087903A1 (en) 2023-03-23
US11285139B2 (en) 2022-03-29
CN111065394A (zh) 2020-04-24
JP7196157B2 (ja) 2022-12-26
MX2020001732A (es) 2020-03-20
WO2019045121A1 (en) 2019-03-07
US20200306238A1 (en) 2020-10-01
KR102680786B1 (ko) 2024-07-02
KR20200046022A (ko) 2020-05-06

Similar Documents

Publication Publication Date Title
US11285139B2 (en) Treatment of CNS conditions
US8877800B2 (en) Kappa-opiate agonists for the treatment of diarrhea-predominant irritable bowel syndrome
US11123332B2 (en) Gaboxadol for reducing risk of suicide and rapid relief of depression
US12465583B2 (en) Methods of treatment using an mTORC1 modulator
IL310065A (en) Methods for treating seizure disorders and Prader-Willi syndrome
KR20120050512A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
US8222278B2 (en) Treatment of attention-deficit/hyperactivity disorder
JP2012508792A (ja) エプリバンセリンを使用して睡眠障害を治療する方法
HK1139860B (en) Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230605

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240807

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240903

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250106

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250505

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250505

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250724

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250828

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250828